Development of HIV-1 Nef vaccine components: Immunogenicity study of Nef mutants lacking myristoylation and dileucine motif in mice

Vaccine

Volumn 20, Issue 27-28, 2002, Pages 3413-3421

  Liang, Xaioping ^a   Fu, Tong Ming ^a   Xie, Hong ^a   Emini, Emilio A ^a   Shiver, John W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

CTL; HIV 1; Nef

Indexed keywords

ALANINE; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MUTANT PROTEIN; NEF PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG SAFETY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOGENETICS; MOUSE; MOUSE STRAIN; MYRISTYLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ENGINEERING; PROTEIN FUNCTION;

AIDS VACCINES; AMINO ACID MOTIFS; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; BASE SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DIPEPTIDES; DNA, VIRAL; EPITOPES; FEMALE; GENE PRODUCTS, NEF; GENES, NEF; HIV-1; HUMANS; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; MYRISTIC ACIDS; PROTEIN ENGINEERING; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC;

EID: 0037056018     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00308-0     Document Type: Article

References (35)

1. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:1994;6103-6110.
2. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W.et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:1994;4650-4655.
3. Betts M.R., Krowka J.F., Kepler T.B., Davidian M., Christopherson C., Kwok S.et al. Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1 infected long-term survivors. AIDS Res. Hum. Retroviruses. 15:1999;1219-1228.
4. + T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189:1999;991-998.
5. + lymphocytes. Science. 283:1999;857-860.
6. Barouch D.H., Santra S., Schmitz J.E., Kuroda M.J., Fu T.M., Wagner W.et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science. 290:2000;486-492.
7. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I.et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 292:2001;69-74.
8. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K.et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 415:2002;331-335.
9. Yu G., Felsted R.L. Effect of myristoylation on p27 nef subcellular distribution and suppression of HIV-LTR transcription. Virology. 187:1992;46-55.
10. Kaminchik J., Bashan N., Itach A., Sarver N., Gorecki M., Panet A. Genetic characterization of human immunodeficiency virus type 1 nef gene products translated in vitro and expressed in mammalian cells. J. Virol. 65:1991;583-588.
11. Ranki A., Lagerstedt A., Ovod V., Aavik E., Krohn K.J. Expression kinetics and subcellular localization of HIV-1 regulatory proteins Nef, Tat and Rev in acutely and chronically infected lymphoid cell lines. Arch. Virol. 139:1994;365-378.
12. Chowers M.Y., Spina C.A., Kwoh T.J., Fitch N.J., Richman D.D., Guatelli J.C. Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene. J. Virol. 68:1994;2906-2914.
13. Birch M.R., Learmont J.C., Dyer W.B., Deacon N.J., Zaunders J.J., Saksena N.et al. An examination of signs of disease progression in survivors of the Sydney Blood Bank Cohort (SBBC). J. Clin. Virol. 22:2001;263-270.
14. Korber BTM, Moore JP, Brander C, Walker BD, Haynes BF, Koup RA, editors. 1999 HIV molecular immunology compendium. Los Alamos (NM): Theoretical Biology and Biophysics, Los Alamos National Laboratory, 1999.
15. Schrager J.A., Marsh J.W. HIV-1 Nef increases T cell activation in a stimulus-dependent manner. Proc. Natl. Acad. Sci. U.S.A. 96:1999;8167-8172.
16. Swingler S., Mann A., Jacque J., Brichacek B., Sasseville V.G., Williams K.et al. HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages [see comments]. Nat. Med. 5:1999;997-1003.
17. Aiken C., Konner J., Landau N.R., Lenburg M.E., Trono D. Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell. 76:1994;853-864.
18. Collins K.L., Baltimore D. HIV's evasion of the cellular immune response. Immunol. Rev. 168:1999;65-74.
19. Hanna Z., Kay D.G., Rebai N., Guimond A., Jothy S., Jolicoeur P. Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell. 95:1998;163-175.
20. Pandori M.W., Fitch N.J., Craig H.M., Richman D.D., Spina C.A., Guatelli J.C. Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein. J. Virol. 70:1996;4283-4290.
21. Bresnahan P.A., Yonemoto W., Ferrell S., Williams Herman D., Geleziunas R., Greene W.C. A dileucine motif in HIV-1 Nef acts as an internalization signal for CD4 down regulation and binds the AP-1 clathrin adaptor. Curr. Biol. 8:1998;1235-1238.
22. Shiver J.W., Davies M.E., Perry H.C., Freed D.C., Liu M.A. Humoral and cellular immunities elicited by HIV-1 vaccination. J. Pharm. Sci. 85:1996;1317-1324.
23. Li Z., Howard A., Kelley C., Delogu G., Collins F., Morris S. Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences. Infect. Immun. 67:1999;4780-4786.
24. Malin A.S., Huygen K., Content J., Mackett M., Brandt L., Andersen P.et al. Vaccinia expression of Mycobacterium tuberculosis-secreted proteins: tissue plasminogen activator signal sequence enhances expression and immunogenicity of M. tuberculosis Ag85. Microbes Infect. 2:2000;1677-1685.
25. Rammensee H.G., Friede T., Stevanovic S. MHC ligands and peptide motifs: first listing. Immunogenetics. 41:1995;178-228.
26. Falk K., Rotzschke O. Consensus motifs and peptide ligands of MHC class I molecules. Semin. Immunol. 5:1993;81-94.
27. Welker R., Harris M., Cardel B., Krausslich H.G. Virion incorporation of human immunodeficiency virus type 1 nef is mediated by a bipartite membrane-targeting signal: analysis of its role in enhancement of viral infectivity. J. Virol. 72:1998;8833-8840.
28. Wang J.K., Kiyokawa E., Verdin E., Trono D. The Nef protein of HIV-1 associates with rafts and primes T cells for activation. Proc. Natl. Acad. Sci. U.S.A. 97:2000;394-399.
29. Aldrovandi G.M., Gao L., Bristol G., Zack J.A. Regions of human immunodeficiency virus type 1 nef required for function in vivo. J. Virol. 72:1998;7032-7039.
30. Flaherty M.T., Barber S.A., Clements J.E. Neurovirulent simian immunodeficiency virus incorporates a Nef-associated kinase activity into virions. AIDS Res. Hum. Retroviruses. 14:1998;163-170.
31. Craig H.M., Pandori M.W., Guatelli J.C. Interaction of HIV-1 Nef with the cellular dileucine-based sorting pathway is required for CD4 down-regulation and optimal viral infectivity. Proc. Natl. Acad. Sci. U.S.A. 95:1998;11229-11234.
32. Tobery T.W., Siliciano R.F. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J. Exp. Med. 185:1997;909-920.
33. Tobery T., Siliciano R.F. Induction of enhanced CTL-dependent protective immunity in vivo by N-end rule targeting of a model tumor antigen. J. Immunol. 162:1999;639-642.
34. Asakura Y., Hamajima K., Fukushima J., Mohri H., Okubo T., Okuda K. Induction of HIV-1 Nef-specific cytotoxic T lymphocytes by Nef-expressing DNA vaccine. Am. J. Hematol. 53:1996;116-117.
35. Michel F., Hoffenbach A., Froussard P., Langlade-Demoyen P., Kaczorek M., Kieny M.P.et al. HIV-1 env, nef, and gag-specific T-cell immunity in mice: conserved epitopes in nef p27 and gag p25 proteins. AIDS Res. Hum. Retroviruses. 8:1992;469-478.